Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Medicinova Inc (NQ: MNOV )

1.355 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 1.355
Bid (Size) 1.310 (5)
Ask (Size) 1.410 (23)
Prev. Close 1.355
Today's Range 1.355 - 1.355
52wk Range 1.260 - 2.660
Shares Outstanding 49,046,246
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
From MediciNova, Inc.
Via GlobeNewswire

Performance

YTD
-17.88%
-17.88%
1 Month
-1.81%
-1.81%
3 Month
-10.86%
-10.86%
6 Month
-31.22%
-31.22%
1 Year
-37.84%
-37.84%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why MariaDB Shares Are Trading Higher By Around 100%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
From MediciNova, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
From MediciNova, Inc.
Via GlobeNewswire
Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Is Neuro-Oncology-Focused MediciNova Stock Trading Higher Today?
Via Benzinga
Why Applied UV Shares Are Trading Higher By Around 96%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
From MediciNova, Inc.
Via GlobeNewswire
MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Receives Gene Therapy Milestone Payment
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
From MediciNova, Inc.
Via GlobeNewswire
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology
From MediciNova, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.